An observational study in Lymphoma, Hodgkin Lymphoma and T-cell Lymphoma, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-17.
Sponsored by National Taiwan University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Lymphoma with a site in Taiwan — 11 open to participants now, 18 under way, 7 of them phase 3. Lymphoma · Taiwan.
Among the 40 studies in Lymphoma with a site in Taiwan, this one is one of 4 that started in 2024, is one of 7 observational ones, reaches primary completion later than 11 of the 17 other live ones, and was the 38th registered.
3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.
Browse Lymphoma studies →11 of the 40 studies in Lymphoma with a site in Taiwan are open now. Recruiting first, the newest first:
Kaohsiung Medical University Chung-Ho Memorial Hospital · Sites in Taiwan
Ages 18–80
Hoffmann-La Roche · Sites in Taiwan, United States, Australia and 10 more countries
Ages 18+
FBD Biologics Limited · Sites in Taiwan, United States, China
Ages 18+
National Taiwan University Hospital · Sites in Taiwan
Ages 18+
Dren Bio · Sites in Taiwan, United States, Australia and 6 more countries
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 10 · Phase 3 11 · Phase 4 1
First in 2005; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 168 across 394 observational studies indexed under Lymphoma.
Median enrollment 80 across the 33 interventional studies, 50 across the 7 observational. Of the 20 that completed or were terminated, 8 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 40 have an industry lead sponsor. The 10 most frequent:
National Taiwan University Hospital is the lead sponsor of 2,617 studies on the registry; 575 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.
National Taiwan University Hospital has 3 studies filed under Lymphoma — fewer than ten, so there is no comparison to draw.
9 of the studies in Lymphoma with a site in Taiwan that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
| NCT06356129Phase 3CelgeneStudy to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma | 2027-08-09 |
| NCT06084936Phase 3Hoffmann-La RocheA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | 2027-08-31 |
| NCT04662255Phase 3Loxo Oncology, Inc.Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) | 2027-11 |
| NCT05475925Dren BioA Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | 2026-12 |
Add all 9 to your calendar (.ics) → With an account.
Among the 40 studies in Lymphoma with a site in Taiwan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Lymphoma is a prevalent lymphoid malignancy globally and in Taiwan. Large B-cell lymphoma (LBCL) is the most common subtype of aggressive B-cell lymphoma. LBCL's aggressive nature manifests through extranodal involvement, severe symptoms, and relative refractoriness to therapies, leading to a 5-year overall survival rate of 60-70% across developed countries and poorer outcomes in high-risk patients with primary refractory disease. Chemoimmunotherapy remains the primary treatment for LBCL, requiring comprehensive assessment through clinical and imaging examinations, biomarkers, and molecular testing. Currently, computed tomography (CT) and positron emission tomography (PET) scans are the standard modalities for treatment response evaluation, though their radioactive nature calls for the development of safer alternatives. Circulating tumor DNA (ctDNA) analysis has emerged as a promising field, providing insights into tumor molecular characteristics, clinical status, and treatment response by analyzing DNA fragments released from tumor cells into the bloodstream. Dynamic monitoring of ctDNA during treatment can effectively gauge therapeutic efficacy-decreasing ctDNA concentrations suggest successful treatment, while increasing levels may indicate treatment failure or tumor recurrence. The detection of ctDNA has been much improved through advances in next-generation sequencing (NGS) technologies, particularly taking advantage of analyzing phased variants, consecutive gene mutations on the same chromosome, enhances the sensitivity and specificity.
pathology proven lymphoma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Pathology proven lymphoma
Exclusion Criteria:
Pathology proven lymphoma
Diagnostic Test: ctDNA analyzed by phased variant
this observational cohort study is to investigate the correlation between ctDNA analyzed by phased variant and the early outcome of the disease.
Correlation between ctDNA analyzed by phased variant and early outcome of lymphoma
The primary endpoint of this observational cohort study is to investigate the correlation between ctDNA analyzed by phased variant and the early outcome of aggressive B cell lymphoma
Time frame: From the date of enrollment, up to 24 months or date of death from any cause.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for Jul 2027, 35 months after the start.
Of 141 non-industry observational studies under Lymphoma, half reached primary completion within 90 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 269. This study's planned 35 months is below that.
Counting every sponsor, half of 160 studies reached it within 82 months; a quarter within 39 and three quarters within 269.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Taiwan University Hospital →